How it works
Our platform enables flexible scaling with single organoid precision. Coupled with state-of-the art analytical technologies, BrainZell’s organoid platform is especially suitable for early drug discovery research in target identification, phenotypic screening, lead optimization, neurosafety and translational research.
Our platform is designed to handle large volumes of experiments simultaneously, drastically reducing turnaround times and accelerating the path to actionable results.
Our models offer possibility for microglia co-culture, enabling the discovery of the neuroimmune aspects of disease progression and treatment response.
Customized hiPSCs Sourcing
Choose what works best for you application
a diverse range of genetic backgrounds from established biobanks.
collaborating with clinical partners to obtain patient-specific cells.
utilize your own iPSC lines for personalized applications.
Assays
Our platform enables single exposure to long term treatment possibilities
Tests per week
Organoids